A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours

Study identifier:D9450C00001

ClinicalTrials.gov identifier:NCT05397171

EudraCT identifier:2021-005438-41

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours

Medical condition

Urinary Bladder Neoplasms

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD8853, Zirconium-89 crefmirlimab berdoxam

Sex

All

Actual Enrollment

17

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 07 Jun 2022
Primary Completion Date: 06 Jun 2023
Study Completion Date: 06 Jun 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

ImaginAb, Inc.

Inclusion and exclusion criteria